Clinical trials
Staging clinical trials
Below are recruiting staging clinical trials, each written for real people, not researchers. We’re tracking 1,893 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT06167109Recruiting
NBI and MRI to guide radiation planning for one-sided nose cancer
This trial tests whether combining a special scope (NBI) with MRI scans can help doctors better target radiation therapy for a specific type of nose/throat cancer that affects only one side. It aims to make treatment more precise and reduce side effects.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06229158Recruiting
Sexual health needs in advanced cancer: a quality-of-life study
This study asks people with advanced cancer (and their partners) about their sexual health and quality of life. It aims to understand what needs are not being met and how to better support patients and their partners.
LyonAges 18 years+ - NCT06181396Recruiting
Timing of oxytocin in second stage of labor
This study looks at when oxytocin is started during the pushing phase of labor to understand if timing affects outcomes for the mother and baby.
HaifaAges 18 years+ - NCT06083870RecruitingPhase 1
Oba01 for advanced lung cancer that has progressed
This trial tests a new drug called Oba01 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after other treatments. It targets a protein called DR5 found on cancer cells.
ShanghaiAges 18–75 - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT05718323RecruitingPhase 2
Niraparib with immunotherapy maintenance for advanced small-cell lung cancer
This trial tests whether adding niraparib (a pill cancer medicine) to ongoing immunotherapy maintenance can help people with advanced small-cell lung cancer live longer or better. It is for tumors that show a specific protein marker (SLFN11) and that did not worsen after standard first-line chemo-immunotherapy.
AngersAges 18 years+ - NCT05738434RecruitingPhase 2
Testing immunotherapy plus targeted drug with short chemo for esophagus cancer
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
Zhengzhou, HenanAges 18–75 - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT05441566Enrolling by invitation
Checking MRD after surgery in early lung cancer
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
ShenzhenAges 18–100 - NCT05407480Recruiting
Treatment guidance study for children with Hodgkin lymphoma
This study is for children with “classical” Hodgkin lymphoma to help guide the best treatment plan. It may help your care team choose therapy based on what has worked for similar children.
Paris, FranceAges birth–18 years - NCT04992780RecruitingPhase 2
Hypo-fractionated radiation versus standard radiation for lung cancer
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
Kansas City, KansasAges 18 years+ - NCT04731610Recruiting
Radiation after thymoma surgery versus watchful waiting
This trial compares two approaches after complete surgical removal of stage IIb or III thymoma: targeted radiation (conformal post-operative radiotherapy) or no further treatment right away (surveillance). It aims to see whether adding radiation lowers the risk of the cancer coming back without causing unacceptable side effects.
CaenAges 18–75 - NCT05204212Recruiting
Heart procedure to close an atrial clot risk pouch in kidney failure
This trial tests a heart procedure that closes a part of the heart called the left atrial appendage to help prevent stroke in people with an irregular heartbeat (atrial fibrillation) and very advanced kidney disease. It’s mainly for patients who can take the needed blood-thinner medicines and who do not already have a clot in that pouch.
Lübeck, Schleswig-HolsteinAges 18 years+ - NCT05284318Recruiting
Antibiotic plans and outcomes after two-stage joint revision
This study looks at how antibiotic treatment (especially the course length and approach) relates to infection control and results after a two-step surgery for joint infections. If you’ve had a spacer placed, finished at least 6 weeks of antibiotics, and then had the second surgery, the research team may want to follow your outcomes over time.
Fuzhou, FujianAges 18 years+ - NCT04365036RecruitingPhase 3
Check if PD-1 plus chemo-radiation helps early nasal lymphoma
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Guangzhou, GuangdongAges 18–75 - NCT05821140Recruiting
Assessing jaw and bite function in children with oral health issues
This study looks at how a child’s mouth, jaw, and biting function work in different dental and oral health situations. It may help clinicians better understand what support or treatments children need.
Clermont-FerrandAges 3–17 - NCT05508126Recruiting
MRI and special CT scans to study stomach cancer
This trial studies how two types of scans—multi-parameter MRI and special CT (dual-energy CT)—look in people with confirmed stomach cancer before surgery. It may help doctors better understand the cancer and improve planning based on scan features.
NanjingAges 18 years+ - NCT04046042Recruiting
Virtual reality during dialysis, comparing first vs last
This trial tests whether using virtual reality during hemodialysis affects how patients feel or do during treatment. It compares using virtual reality at the beginning of the dialysis session versus the end.
Manises, ValenciaAges 18 years+ - NCT03375983RecruitingPhase 1/Phase 2
Immune treatment with malaria cells for advanced solid cancers
This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT05387005Recruiting
Check who should be tested for H. pylori to prevent stomach cancer
This study looks at a screening plan to prevent stomach cancer by identifying people who should be tested and treated for H. pylori, a common stomach germ. If you have never had H. pylori testing or treatment, the trial may help determine the best approach for prevention.
TaipeiAges 20 years+ - NCT05623319RecruitingPhase 2
Pembrolizumab plus olaparib for extensive small cell lung cancer
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
Meldola, Forlì CesenaAges 18 years+ - NCT05530057RecruitingPhase 2
Eribulin plus or minus trastuzumab for HER2-positive breast cancer
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
SeoulAges 18 years+ - NCT04637711Recruiting
Surgery for stubborn granulomatous breast inflammation
This study looks at surgical treatment for granulomatous lobular mastitis that has not been improving with non-surgical care. It may help people with more widespread or complicated breast inflammation, especially when there are abscesses or skin breakdown.
Wuhan, HubeiAges 18–60
Hear when a new Staging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for staging?
- Yes. Clin2 currently lists 1,893 recruiting staging studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a staging trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a staging trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.